Cap out-of-pocket insulin costs at $35 per month.

Donald Norcross · New Jersey · Democratic

policy impact 0.77 specificity 0.95 extraction confidence 98%

Contest this claim

Occurrences

I have been on the forefront of fighting to allow Medicare to negotiate prescription drug prices, limit the out-of-pocket costs to $35 a month for life saving insulin and reducing the cost of prescriptions for all families.

Commits to keep insulin affordable by limiting monthly out-of-pocket costs.

Improving Health Care - Donald Norcross
campaign · campaign_site · model gpt-5.4-mini

Evidence

Axios reports that the Senate Health Committee backed an amendment by a 15-8 vote to extend a $35 monthly insulin cap to people with private insurance and add a pilot for uninsured patients. That shows the broader version is still being pursued rather than fully enacted.

Recent congressional action indicates the wider private-insurance promise remains pending, so the commitment is not fully delivered.

unresolved later_term A for effort

Insulin cost cap gets another look in Congress
secondary · model gpt-5.4-mini · confidence 78%

Contest this evidence item

Kiplinger says Medicare beneficiaries' insulin costs remain capped at $35 per month in 2026. That confirms the federal cap exists, but only within Medicare coverage rather than as a universal out-of-pocket limit.

The insulin cap is in force for Medicare beneficiaries, which supports a partial delivery assessment rather than full delivery of a broad cap.

partial later_term

10 Medicare Changes to Watch in 2026
secondary · model gpt-5.4-mini · confidence 90%

Contest this evidence item

Assessments

partial later_term

A $35 monthly insulin cap exists for Medicare beneficiaries, but the broader promise of capping out-of-pocket insulin costs at $35 for everyone has not been fully enacted. Recent congressional action shows the wider version is still pending, so this is only partial delivery rather than full fulfillment. There is no clear evidence here that Donald Norcross directly drove the outcome to completion, so the result should not be credited as a full delivery.

provider codex_cli · model gpt-5.4-mini · confidence 92%